Investor Presentaiton

INVESTMENT HIGHLIGHTS ☐☐☐ שיי High quality assets in high-growth markets Blue-chip pedigree management team Significant embedded growth potential Demonstrated ability to consolidate Organizational emphasis on R&D and innovation Executable path to $260M+ Adj. EBITDA in 2022 Florida will remain a supply-strained market and is expected to legalize adult-use in the next 24 months¹ Massachusetts has significant upside with the addition of a 3rd retail store and expected wholesale opportunities Pennsylvania operations expected to commence in 2021 with plans for 6 dispensaries by year end 1 1,2 ADJUSTED EBITDA BRIDGE: 2020A - 2022E2 ($USD in millions) 18 2020A ADJ. EBITDA³ REPRESENTS EXPECTED ORGANIC GROWTH FROM EXISTING FOOTPRINT 159 FLORIDA 99 66 MASS. 32 3 PENN. NEVADA 60 TEXAS IN-PROCESS & HIGH-CONFIDENCE NEW MARKET 7 GEORGIA (27) CORP. SG&A 264 2022E ADJ. EBITDA ADULT-USE UPSIDE, I ADD'L MARKETS | (NJ, VA), BEVERAGE, CBN SLEEP AID, RARE CANNABINOID-BASED PRODUCTS 1. See "Forward-Looking Statements" disclaimer on pages 3-4 and financial assumptions on pages 57-58. 2. See "Non-GAAP Measures, Reconciliation and Discussion" disclaimer on page 5 and Adjusted EBITDA reconciliation on page 59. 3. 2020 financials are preliminary and are subject to change upon finalization of Parallel's audited financials. 23 3

View entire presentation